Printing thermoelectric inks toward next-generation energy and thermal devices

2021 ◽  
Author(s):  
Minxiang Zeng ◽  
Duncan Zavanelli ◽  
Jiahao Chen ◽  
Mortaza Saeidi-Javash ◽  
Yipu Du ◽  
...  

This review provides a framework for printing thermoelectric materials and devices by discussing recent progress in thermoelectric ink chemistry and formulations, printing methods, flexible/conformable device designs, and energy/thermal applications.

2021 ◽  
Vol 2 (6) ◽  
pp. 2170015
Author(s):  
Chengzhi Zhang ◽  
Fei Wang ◽  
Jian Han ◽  
Shuo Bai ◽  
Jun Tan ◽  
...  

2021 ◽  
Vol 151 ◽  
pp. 111640
Author(s):  
Peng Du ◽  
Liang Cao ◽  
Bao Zhang ◽  
Chunhui Wang ◽  
Zhiming Xiao ◽  
...  

2016 ◽  
Vol 11 (12) ◽  
pp. C12058-C12058 ◽  
Author(s):  
N. Demaria ◽  
M.B. Barbero ◽  
D. Fougeron ◽  
F. Gensolen ◽  
S. Godiot ◽  
...  

Materials ◽  
2015 ◽  
Vol 8 (2) ◽  
pp. 732-750 ◽  
Author(s):  
Qingshuo Wei ◽  
Masakazu Mukaida ◽  
Kazuhiro Kirihara ◽  
Yasuhisa Naitoh ◽  
Takao Ishida

2015 ◽  
Vol 52 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Kyu Hyoung Lee ◽  
Jong-Young Kim ◽  
Soon-Mok Choi

Nanoscale ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 1247-1268 ◽  
Author(s):  
H. H. Huang ◽  
Xiaofeng Fan ◽  
David J. Singh ◽  
W. T. Zheng

The diversity of electronic characteristics of TMDs ranging from the semiconducting, semi-metallic to metallic have broadened their application in catalysis, electrode materials and next-generation functional electronic devices.


2019 ◽  
Vol E102.C (4) ◽  
pp. 324-332
Author(s):  
Hiroshi ARUGA ◽  
Keita MOCHIZUKI ◽  
Tadashi MURAO ◽  
Mizuki SHIRAO

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 742 ◽  
Author(s):  
Masayuki Takeda ◽  
Kazuko Sakai ◽  
Takayuki Takahama ◽  
Kazuya Fukuoka ◽  
Kazuhiko Nakagawa ◽  
...  

Recent progress in understanding the molecular basis of cancer—including the discovery of cancer-associated genes such as oncogenes and tumor suppressor genes—has suggested that cancer can become a treatable disease. The identification of driver oncogenes such as EGFR, ALK, ROS1, BRAF and HER2 has already been successfully translated into clinical practice for individuals with solid tumor. Next-generation sequencing (NGS) technologies have led to the ability to test for multiple cancer-related genes at once with a small amount of cells and tissues. In Japan, several hospitals have started NGS-based mutational profiling screening in patients with solid tumor in order to guide patients to relevant clinical trials. The Ministry of Health, Labor, and Welfare of Japan has also approved several cancer gene panels for use in clinical practice. However, there is an urgent need to develop a medical curriculum of clinical variant interpretation and reporting. We review recent progress in the implementation of NGS in Japan.


Sign in / Sign up

Export Citation Format

Share Document